FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2810367576> ?p ?o ?g. }

• W2810367576 endingPage "1420" @default.
• W2810367576 startingPage "1412" @default.
• W2810367576 abstract "Abstract Background Mastocytosis is characterized by the accumulation of aberrant mast cells (MC). Patients suffering from mastocytosis suffer from a wide range of symptoms due to increased levels of MC mediators. It would therefore be of great benefit to inhibit MC mediator release. However, to date there are few drugs available that are known to effectively lower MC mediator levels. The evidence for the involvement of the janus kinase 2 (JAK2)—signal transducer and activation of transcription 5 (STAT5) signalling pathway in MC activation is slowly accumulating. Interference with the JAK2‐STAT5 pathway might inhibit MC mediator release. Ruxolitinib, a JAK1/JAK2 inhibitor, indeed decreases symptoms like pruritus and fatigue in patients with myeloproliferative neoplasms. Yet, detailed studies on how ruxolitinib affects human mast cell activity are lacking. Objective To investigate the effect of JAK1/2‐inhibition with ruxolitinib in the human mast cell lines LAD2 and HMC1. Methods LAD2 and HMC1 were stimulated with substance P, codeine or the calcium ionophore A23817. The effect of ruxolitinib on mast cell degranulation (via measurement of β‐hexosaminidase, histamine release and CD63 membrane expression) and IL‐6, IL‐13, MCP‐1 and TNF‐α production was investigated. The involvement of STAT5 activation was explored using the selective STAT5 inhibitor pimozide. Results Ruxolitinib effectively inhibited codeine‐ and substance P‐induced degranulation in a concentration‐dependent manner. Ruxolitinib also significantly inhibited the production of IL‐6, TNF‐α and MCP‐1 as induced by A23817 and substance P. Selective STAT5 inhibition with pimozide resulted in diminished degranulation and inhibition of cytokine production as induced by A23817 and substance P. Conclusions & clinical relevance This study demonstrates that the JAK1/JAK2 inhibitor ruxolitinib can inhibit MCactivity, possibly through prevention of STAT5 activation. This renders the JAK‐STAT pathway as an interesting target for therapy to release symptom burden in mastocytosis and many other MC mediator‐related diseases." @default.
• W2810367576 created "2018-07-10" @default.
• W2810367576 creator A5004123017 @default.
• W2810367576 creator A5010981455 @default.
• W2810367576 creator A5012906341 @default.
• W2810367576 creator A5016878392 @default.
• W2810367576 creator A5034070860 @default.
• W2810367576 creator A5058045078 @default.
• W2810367576 creator A5065911146 @default.
• W2810367576 date "2018-08-03" @default.
• W2810367576 modified "2023-10-14" @default.
• W2810367576 title "The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release" @default.
• W2810367576 cites W1146082955 @default.
• W2810367576 cites W1578265282 @default.
• W2810367576 cites W1763726136 @default.
• W2810367576 cites W1912863285 @default.
• W2810367576 cites W1913762249 @default.
• W2810367576 cites W193074916 @default.
• W2810367576 cites W1974255118 @default.
• W2810367576 cites W1984015634 @default.
• W2810367576 cites W1986585141 @default.
• W2810367576 cites W1990991524 @default.
• W2810367576 cites W2002117801 @default.
• W2810367576 cites W2013072710 @default.
• W2810367576 cites W2022660538 @default.
• W2810367576 cites W2030430614 @default.
• W2810367576 cites W2032278706 @default.
• W2810367576 cites W2042563856 @default.
• W2810367576 cites W2046214587 @default.
• W2810367576 cites W2050696396 @default.
• W2810367576 cites W2056811697 @default.
• W2810367576 cites W2057650885 @default.
• W2810367576 cites W2069276819 @default.
• W2810367576 cites W2079645940 @default.
• W2810367576 cites W2083890182 @default.
• W2810367576 cites W2092346711 @default.
• W2810367576 cites W2098157541 @default.
• W2810367576 cites W2103280326 @default.
• W2810367576 cites W2114043889 @default.
• W2810367576 cites W2114305100 @default.
• W2810367576 cites W2135264802 @default.
• W2810367576 cites W2137549989 @default.
• W2810367576 cites W2139531248 @default.
• W2810367576 cites W2142506642 @default.
• W2810367576 cites W2161021913 @default.
• W2810367576 cites W2258838324 @default.
• W2810367576 cites W2264962020 @default.
• W2810367576 cites W2284068271 @default.
• W2810367576 cites W2326374920 @default.
• W2810367576 cites W2376898829 @default.
• W2810367576 cites W2410552124 @default.
• W2810367576 cites W2472403803 @default.
• W2810367576 cites W2529284985 @default.
• W2810367576 cites W2535682874 @default.
• W2810367576 cites W2555297165 @default.
• W2810367576 cites W2568737301 @default.
• W2810367576 cites W2584159511 @default.
• W2810367576 cites W2605999253 @default.
• W2810367576 cites W2732980547 @default.
• W2810367576 cites W2742246395 @default.
• W2810367576 cites W2752373471 @default.
• W2810367576 cites W935880247 @default.
• W2810367576 doi "https://doi.org/10.1111/cea.13217" @default.
• W2810367576 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29939445" @default.
• W2810367576 hasPublicationYear "2018" @default.
• W2810367576 type Work @default.
• W2810367576 sameAs 2810367576 @default.
• W2810367576 citedByCount "39" @default.
• W2810367576 countsByYear W28103675762019 @default.
• W2810367576 countsByYear W28103675762020 @default.
• W2810367576 countsByYear W28103675762021 @default.
• W2810367576 countsByYear W28103675762022 @default.
• W2810367576 countsByYear W28103675762023 @default.
• W2810367576 crossrefType "journal-article" @default.
• W2810367576 hasAuthorship W2810367576A5004123017 @default.
• W2810367576 hasAuthorship W2810367576A5010981455 @default.
• W2810367576 hasAuthorship W2810367576A5012906341 @default.
• W2810367576 hasAuthorship W2810367576A5016878392 @default.
• W2810367576 hasAuthorship W2810367576A5034070860 @default.
• W2810367576 hasAuthorship W2810367576A5058045078 @default.
• W2810367576 hasAuthorship W2810367576A5065911146 @default.
• W2810367576 hasBestOaLocation W28103675761 @default.
• W2810367576 hasConcept C1122143 @default.
• W2810367576 hasConcept C126322002 @default.
• W2810367576 hasConcept C170493617 @default.
• W2810367576 hasConcept C185592680 @default.
• W2810367576 hasConcept C203014093 @default.
• W2810367576 hasConcept C2776112149 @default.
• W2810367576 hasConcept C2778690821 @default.
• W2810367576 hasConcept C2779391668 @default.
• W2810367576 hasConcept C2779726688 @default.
• W2810367576 hasConcept C2780007613 @default.
• W2810367576 hasConcept C2780076729 @default.
• W2810367576 hasConcept C49802076 @default.
• W2810367576 hasConcept C502942594 @default.
• W2810367576 hasConcept C55493867 @default.
• W2810367576 hasConcept C62478195 @default.
• W2810367576 hasConcept C71924100 @default.

• next